金吾财讯 | 再鼎医药(ZLAB)盘前涨超4%,截至发稿,报36.50美元。消息面上, 中金发布研报称,6月30日,Amgen/再鼎公布Bemarituzumab(贝玛妥珠单抗)联合化疗一线治疗FGFR2b阳性胃癌患者III期临床研究(FORTITUDE-101)中期分析数据,达到了其主要终点总生存期(OS),显示出具有显著统计学意义和临床意义的改善。再鼎拥有该产品大中华区开发和商业化的独家授权。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.